Drug-induced thrombocytopenia associated with trastuzumab in a patient with HER2-positive recurrent gastric cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2192-3183
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Drug-induced thrombocytopenia associated with trastuzumab in a patient with HER2-positive recurrent gastric cancer ; day:2 ; month:11 ; year:2021 ; pages:1-4
International Cancer Conference journal ; (2.11.2021), 1-4
- Urheber
-
Takano, Yuko
Furune, Satoshi
Miyai, Yuki
Morita, Sachi
Inoue, Megumi
Shimokata, Tomoya
Sugishita, Mihoko
Mitsuma, Ayako
Maeda, Osamu
Ando, Yuichi
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s13691-021-00520-z
- URN
-
urn:nbn:de:101:1-2022011621182836798827
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Takano, Yuko
- Furune, Satoshi
- Miyai, Yuki
- Morita, Sachi
- Inoue, Megumi
- Shimokata, Tomoya
- Sugishita, Mihoko
- Mitsuma, Ayako
- Maeda, Osamu
- Ando, Yuichi
- SpringerLink (Online service)
Ähnliche Objekte (12)
Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
Panitumumab-Associated Drug-Induced Immune Thrombocytopenia in a Patient with Colorectal Cancer
NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab
Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
Long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
Predictors of trastuzumab-induced cardiotoxicity among racially and ethnically diverse patients with HER2-positive breast cancer
Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
Panitumumab-Associated Drug-Induced Immune Thrombocytopenia in a Patient with Colorectal Cancer
NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab
Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
Long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
Predictors of trastuzumab-induced cardiotoxicity among racially and ethnically diverse patients with HER2-positive breast cancer
Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
Panitumumab-Associated Drug-Induced Immune Thrombocytopenia in a Patient with Colorectal Cancer
NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab
Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
Long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer